RT Journal Article
SR Electronic
T1 A multitracer dopaminergic PET study of YOPD patients with and without parkin mutations
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 126
OP 126
VO 50
IS supplement 2
A1 Ribeiro, MJ
A1 Thobois, S
A1 Lohmann, Ebba
A1 Tezenas du Montcel, Sophie
A1 Lesage, Suzanne
A1 Pollak, Pierre
A1 Broussolle, Emmanuel
A1 Brice, Alexis
A1 Remy, P
YR 2009
UL http://jnm.snmjournals.org/content/50/supplement_2/126.abstract
AB 126 Objectives To characterize with 18FDOPA, 11C-PE2I and 11C-Raclopride the pattern of dopaminergic lesions in young onset Parkinson’s disease patients (YOPD) carrying or not mutations of the parkin gene. Methods 35 YOPD patients were enrolled (16 with parkin mutation, 19 without). The uptake constant (Ki) of 18FDOPA and the binding potential (BP) of 11C-PE2I (BPDAT) and 11C-Raclopride (BPD2) were calculated in the striatum. Comparisons were made between the two groups of YOPD and between controls and patients. For each radiotracer, parametric images were obtained and a statistical parametric analysis (SPM5) was performed. Correlations between the cognitive and motor status and PET were analysed. Results In YOPD patients, Ki values were reduced to 67% (putamen, Pu) and 39% (caudate, Cd) of normal values (p<0.0001). This decrease was symmetrical and comparable for both patient's groups. No correlation was found between Ki and cognitive or motor status. BPDAT in YOPD, was decreased to 56% (Pu) and 41% (Cd) of normal values (p<0.0001), and did not differ between the two YOPD populations. BPD2 values were reduced (p<0.02) to 17% (Pu) and 28% (Cd) and did not differ between the non-parkin and parkin patients. Moreover, SPM shows a decrease of 18FDOPA and 11C-PE2I uptake in the substantia nigra bilaterally (p<0.001). Conclusions Carriers of parkin mutations are indistinguishable on PET markers of dopaminergic dysfunction, from other YOPD patients with long disease duration.